Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280027 | 0.87 | SLC18A3 (0.50) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL9921710 | 0.85 | HPGD (0.56) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL280117 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL14625164 | 0.81 | HPGD (0.57) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL9918291 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL9918314 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL279955 | 0.77 | HPGD (0.56) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL20261540 | 0.76 | ACHE (0.59) | ALDH1A1HPGDSLC8A1SLC18A3NPC1 | |
| SCHEMBL9921641 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAGAASLC18A3 | |
| SCHEMBL280089 | 0.75 | ALDH1A1 (0.51) | ALDH1A1HPGDLMNAGAASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | ALDH1A1 2047/4885HPGD 1895/4885LMNA 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.